Cancer prognosis has steadily improved over recent decades. In 2025, approximately 85% of patients with cancer were in remission. The growing complexity of oncologic treatments has led to substantial gains in progression-free survival, albeit at the cost of increased cardiotoxic risk. Cardiotoxicity most commonly manifests as heart failure or left ventricular dysfunction. Consequently, the cardiovascular mortality of individuals treated for childhood cancers, as well as of older women treated for breast cancer, now equals or even exceeds oncologic mortality.In response, the European Society of Cardiology has issued its first cardio-oncology guidelines, establishing precise thresholds for left ventricular ejection fraction, longitudinal function (as assessed by echocardiographic strain parameters), and selected cardiac biomarkers. Within this framework, it is crucial to develop robust strategies to predict, enable early detection of, and ideally prevent treatment-related adverse cardiac effects. Rigorous control of traditional cardiovascular risk factors remains the cornerstone of preventing oncology-treatment-induced cardiotoxicity.

To describe cases of intraocular inflammation (IOI) observed after intravitreal injections (IVI) of second-generation anti-VEGF agents in a university hospital over 12months in 2024.

New therapeutic options for gynecological cancers (in particular, targeted therapies and immunotherapies) are associated with potential cardiovascular toxicities that oncologists should be able to identify, detect and manage together with a cardiologist. The first step consists of evaluating the patient's individual cardiovascular risk, regardless of planned oncologic treatment, to determine whether this treatment can be initiated immediately or if cardiological advice is required. In a second step, the risk of cardiovascular toxicity of the selected treatment must be assessed, considering its intrinsic risk and the patient's comorbidities. Once treatment has started, appropriate monitoring should be implemented during administration, and after discontinuation. Beyond general recommendations, specific situations are detailed for initial workup and surveillance relating to most common protocols of chemotherapy, immunotherapy, targeted therapy and associations used in gynecological oncology. If cardiotoxicity occurs (hypertension, QT interval increase, left ventricular dysfunction, troponin increase, myocarditis), the oncologist must be aware of the principles of management, and distinguish between what he can manage on his own and what requires referring to specialists. Prior to rechallenge after cardiotoxicity, multidisciplinary discussion is mandatory to assess the patient's benefit/risk ratio.

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and significantly improved survival in many tumour types. However, blocking the immune system's inhibitory signaling pathways can trigger an excessive immune response against the body's own tissues, leading to immune-related adverse events (irAEs). These can potentially affect any organ system and represent a significant clinical challenge. This article provides a practical overview of irAEs management, with a particular focus on neurological complications. It presents evidence-based strategies for prevention, diagnosis and treatment, and discusses decision criteria for resuming ICI treatment after an irAE.

The goal of this study was to investigate the efficacy and safety of therapeutic switch of intravitreal injections (IVT) from ranibizumab 10mg/mL (Lucentis®) and aflibercept 40mg/mL (Eylea®) to FYB201 (Ranivisio®) in exudative age-related macular degeneration (AMD). This study includes an analysis of the direct medical cost of managing exudative AMD. The data studied included the mean injection interval in the year preceding the switch and the 9 months following, the longest dry interval over this period, the change in central retinal thickness, tolerance data, the sum of visit costs, treatment costs and an estimate of transportation costs.

The growing number of cancer cases induces increasing pressure on oncology and hematology departments, creating the need for alternatives such as hospitalization at home (HAH). The Carfil-HAD pilot study aimed to assess the feasibility and safety of administering short-duration intravenous carfilzomib infusions at home for the treatment of multiple myeloma. Among the 17 patients included, 15 received 128 infusions of Carfilzomib under a combined Outpatient Hospital (OH)/HAH scheme, are evaluable. Deviations from standard operating procedures were monitored, quality of life and satisfaction were evaluated, and a cost-effectiveness analysis compared the mixed OH/HAH model to exclusive OH care. The results confirmed feasibility: of 128 infusions, 42 were performed in OH and 86 in HAH without serious incident or interruption of care, with 96% of deviations classified as minor. Quality of life is not affected by the mixed care organization, and patient satisfaction was very high. From an economic perspective, the OH/HAH model generated savings of €610 per treatment cycle, nearly half the cost of hospital-based care. In conclusion, intravenous administration of carfilzomib in HAH is feasible and safe. This organization could be applied to other oncological therapies to offer a wider range of outpatient's care.

Although immune-mediated colitis is well known and is one of the most common toxicities of Immune Checkpoint Inhibitors (ICIs), the toxicity of these agents to the upper digestive tract is largely unknown and its incidence is probably underestimated. It can affect the stomach and/or the duodenum, and much more rarely the esophagus. Involvement of several segments is common, as is the association with colitis and possibly extra-digestive toxicity(ies). Severity is extremely variable, but severe forms are possible, particularly due to hydro-electrolytic and nutritional repercussions, possible haemorrhagic complications, and much more rarely, a risk of perforation. Many differential diagnoses must be considered. Therapeutic modalities are partly modeled on those of colitis, and the choices must be discussed and validated in multidisciplinary meetings, taking into account the entire "spectrum" of toxicity. We propose a review of the data available in the literature concerning the toxicity of ICIs on the upper digestive tract, illustrated by a few cases from our center.

Chemotherapy drugs affect the cells of everyone who comes into contact with them, including patients and healthcare professionals. Protective measures must be implemented systematically.

Prostate cancer mainly affects older men and is treated with hormone therapy, often in combination with other treatments. Particular attention must be paid to the side effects of treatments that impact patients' quality of life. Comprehensive care and regular monitoring by a multidisciplinary team supported by supportive oncology care, coordinated by an advanced practice nurse or coordinating nurse, ensure optimal and safe care.

Medication-related osteonecrosis of the jaw is a rare but severe complication of antiresorptive or antiangiogenic treatments. Prevention relies on patient education, dental screening prior to therapy, and avoidance of invasive procedures. Diagnosis is based on clinical and radiological criteria, with classification into four stages. Management is multidisciplinary and adapted to disease stage: strict oral hygiene, antibiotics, sequestrectomy, or reconstructive surgery. Regular follow-up and close communication among healthcare providers are key to controlling disease progression and maintaining patients' quality of life.

As the number of cancer treatments increases, new specific toxicities are emerging, requiring early and specialized treatment. The Gustave-Roussy center in Villejuif, near Paris, has set up a multidisciplinary toxicity pathway (ImmunoTox multidisciplinary consultation meeting, day hospital, mobile team). This includes an advanced practice nurse to optimize the management of undesirable effects, improve quality of life and mobilize all related skills.

The harmonization workshops of the leukemia committee of the Société française des cancers de l'enfant (SFCE) aim to establish practical recommendations based on the one hand, on data from the literature and international recommendations and, on the other hand, by consensus in the absence of formally proven data. Adolescent pubescent girls and young adults undergoing intensive chemotherapy treatment may present with heavy uterine bleeding (HUB). Data collected from 25 French centers showed that there was considerable heterogeneity in the management of HUB either in prophylaxis or curative strategy. Analysis of the literature showed that, given the incidence of spontaneous amenorrhea during chemotherapy treatment, there is no indication for systematic prophylaxis of HUB in patients treated for leukemia. In case of proven HUB, non-hormonal treatment and hormonal treatment can be introduced as a matter of urgency. For secondary prophylaxis, various hormonal treatments aiming at achieving prophylactic amenorrhea may be discussed.

Oral adjuvant hormone therapy for early breast cancer, despite its proven importance in terms of survival and prevention of recurrence, does not fall within the scope of clinical pharmacy programs set up for oral anticancer drugs, even though issues of therapeutic adherence have been clearly identified. The aim of our study was to explore the perception of healthcare professionals regarding the prescription and dispensing of this hormone therapy, in order to identify the risks for these patients and determine the clinical pharmacy actions that could address these risks.

Therapeutics used in cancer treatment can cause vestibular ototoxicity, which is particularly challenging to detect due to the frequent occurrence of nausea and vomiting in patients experiencing significant fatigue and stress. An appropriate diagnosis enables optimal symptom correction, reduces the risk of falls, and improves quality of life.

Immune checkpoint inhibitors are now an essential therapy for lung cancer. These monoclonal antibodies are nevertheless responsible for immune-related adverse events. With particular regards for patients with previous autoimmune disease, less is known about the efficacy and safety of immune checkpoint inhibitors, but also about the consequences of steroids or other specific therapies. The aim of this article is to synthesize available data in the literature on immune checkpoint inhibitors experience in patients with both lung cancer and autoimmune disease.

This review aims to evaluate the incidence, clinical impact, and available therapeutic options for the management of gynecomastia induced by hormonal therapy, particularly in the era of androgen receptor pathway inhibitors, in patients with prostate cancer. We analysed data from clinical trials evaluating the incidence of gynecomastia under androgen receptor pathway inhibitors and the efficacy of both prophylactic and curative strategies, primarily tamoxifen and male breast radiotherapy, in patients receiving bicalutamide. Androgen receptor pathway inhibitors monotherapy is associated with high rates of gynecomastia (34 to 55 %), whereas combining androgen receptor pathway inhibitors with chemical castration significantly reduces this risk. Prophylactic tamoxifen significantly decreases gynecomastia incidence (down to 10 % versus 73 % without treatment) with good overall tolerance; prophylactic breast radiotherapy also shows efficacy. In the curative setting, tamoxifen appears more effective than radiotherapy, while surgery remains an invasive fallback option. However, extrapolating results obtained with bicalutamide to second-generation androgen receptor pathway inhibitors remains uncertain due to pharmacological and clinical differences. Gynecomastia could become a major complication of androgen receptor pathway inhibitors monotherapy. To date, tamoxifen and prophylactic breast radiotherapy are the most validated strategies, with the former appearing more effective. Further studies are needed to confirm their specific efficacy and safety in patients treated with androgen receptor pathway inhibitors.

Breast cancer is the most common cancer among women of childbearing age. Despite potentially gonadotoxic treatments, fertility following breast cancer treatment remains satisfactory. Oncofertility has advanced, and an increasing number of patients benefit from oocyte or embryo cryopreservation techniques. Nevertheless, the majority of pregnancies occur spontaneously. Pregnancy does not increase the risk of recurrence, nor does it decrease the overall survival of women, regardless of nodal status or hormone receptor status. Obstetrically, women treated for breast cancer achieve as many live births as the general population, despite an increased incidence of obstetric complications. Breastfeeding is possible and does not appear to affect survival or increase the risk of recurrence. Thus, the most recent data are reassuring regarding the possibility and safety of pregnancy after breast cancer. However, questions remain concerning the management of treatments in the context of a desire for pregnancy. The benefit of combining GnRH agonists with chemotherapy to improve pregnancy chances is being questioned. The interruption period for tamoxifen in an adjuvant setting needs clarification. Finally, new data are required for patients treated with immunotherapy, PARP inhibitors, or cell cycle cyclin inhibitors.

Immune checkpoint inhibitors (ICI) have revolutionized the treatment of solid tumors. However, they can induce immune-related adverse effects (irAEs) that can affect any organ. These irAEs are different from the side effects of traditional oncological treatments and require specific management. Given the increasing use of ICI, first-line care will increasingly need to manage these irAEs. This article aims to assist in the implementation of the guidelines for managing irAEs, with a particular focus on aspects related to first-line care.

Pembrolizumab, a humanized monoclonal antibody targeting PD-1 (programmed cell death protein 1), is employed for various cancers but can induce immune-related adverse events (irAEs) resembling autoimmune or inflammatory conditions. We present the case of a 44-year-old female with lung cancer treated with pembrolizumab who developed lichen sclerosus (LS). Cases of LS related to immune checkpoint inhibitors (ICIs) have been documented, primarily in women. High-potency topical steroids achieve favorable outcomes without immunotherapy discontinuation. Monitoring the development of malignancies is essential, as LS patients face a high-risk of developping squamous cell carcinoma.

Drug-induced immune thrombocytopenia (DIIT) is a rare cause of immune thrombocytopenia, characterized by the formation of drug-dependent antiplatelet antibodies. DIIT can lead to life-threatening hemorrhage. The diagnosis is difficult, relying on the detection of antiplatelet antibodies in patient's serum exclusively in the presence of the implicated drug. The gold standard test is the monoclonal antibody immobilization of platelet antigens (MAIPA), although other techniques (flow cytometry and Luminex®) can be used.